Drugs / DFO-ATEZOLIZUMAB ZR-89
DFO-ATEZOLIZUMAB ZR-89
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04006522 | Oct 2019 → Oct 2025 overdue | renal cell carcinoma | James Brugarolas | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFO-ATEZOLIZUMAB ZR-89 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068595 ↗ |
| Known as | 89Zr-DFO-Atezolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04006522 ↗ |
| Known as | [89Zr]Zr-DFO-ATZ | “Uptake of 89Zr-labeled atezolizumab ([89Zr]Zr-DFO-ATZ) was compared with PD-L1 expression in tumors by IHC through double-blind analyses.” PMID 36074149 ↗ Nov 2022 |
| Route | Other | “89Zr-DFO-Atezolizumab infusion” NCT04006522 ↗ |